Table 1

Baseline demographic, immunological, and clinical characteristics of T1D individuals treated with nonmyeloablative AHSCT

CharacteristicsValues
Total patients included65
Age (years)20.4 ± 5.5
Sex
 Male41
 Female24
BMI (kg/m2)18.1 ± 3.1
HbA1c (mmol/mol)88.7 ± 4.7
C-peptide (ng/mL)0.69 ± 0.04
Autoantibodies
 GAD52
 GAD/ICA4
 GAD/IA2A3
 IAA4
 ICA2
DKA or DK history
 No DKA/DK43
 DKA21
 DK1
HLA-DQB1 allele
 20117
 3038
 5038
 3027
 5015
 3014
 6012
 6022
 4011
 6041
 3091
 2021
 3311
 4021
 6091
 6031
 3041
  • Data are n or mean ± SD. DK, diabetic ketosis; IA2A, insulinoma-2–associated autoantibodies; IAA, insulin autoantibodies; ICA, islet cell cytoplasmic autoantibodies.